This randomised, placebo-controlled trial (n=60) investigates the feasibility of using a single dose of psilocybin (25mg) as a treatment for adults with treatment-resistant major depressive disorder (TRD).
Randomised, placebo-controlled feasibility study in adults (25–80 years) with treatment-resistant depression testing a single 25 mg oral dose of psilocybin with psychological support.
Primary aim is feasibility; outcomes include safety, tolerability, and depressive symptom change following a single dosing session with preparatory and integration therapy.
Single oral dose psilocybin (25 mg) with psychological support.
Placebo control with identical psychological support.
Placebo capsule matched to psilocybin
No inclusion criteria listed.
No exclusion criteria listed.